Skip to main content

Table 1 (abstract P30). Characteristics of study subjects with JIA who started at least 1 DMARD

From: Proceedings of the 2018 Childhood Arthritis and Rheumatology Research Alliance (CARRA) Scientific Meeting

Characteristic (N, % unless otherwise noted) Cases: off DMARDs ≥12 months1 (N=222) Control group 1: off DMARDs <12 months1 (N=323) Control group 2: not off DMARDs >30 days (N=793) P-value2 (cases vs. control groups 1 and 2) P-value2 (cases vs. control group 1)
Demographic
 Age at diagnosis (years), median (IQR) 4.0 (2.0, 8.0) 4.0 (2.0, 8.0) 6.0 (2.0, 11.0) <0.01 0.70
 Time from symptom onset to diagnosis (days), median (IQR) 47 (29, 86) 58 (26, 92) 54 (29, 132) 0.49 0.61
 Time from diagnosis to start of first DMARD (days), median (IQR) 37 (1, 201) 28 (1, 230) 34 (1, 350) 0.59 0.93
 Time from start of DMARD to first DMARD discontinuation (years), median (IQR) 1.9 (1.2, 3.3) 1.9 (1.1, 3.1) - - 0.51
 Time from start of first DMARD to end of follow-up (years), median (IQR) 6.0 (4.4, 8.8) 5.9 (3.9, 8.6) 4.2 (2.8, 6.7) <0.01 0.26
 Female sex 160 (72%) 253 (78%) 605 (76%) 0.13 0.09
 White race 187 (84%) 272 (84%) 646 (82%) 0.47 0.99
 Latino ethnicity 22 (13%) 22 (8%) 83 (12%) 0.83 0.46
 Residence in US 217 (98%) 314 (97%) 770 (97%) 0.61 0.70
Clinical
 JIA category     0.03 0.14
  Systemic 33 (15%) 30 (12%) 107 (14%)   
  RF+ polyarticular 11 (5%) 19 (6%) 98 (12%)   
  Other 178 (80%) 272 (85%) 588 (74%)   
  ≥5 total joints affected 193 (87%) 295 (91%) 719 (91%) 0.15 0.23
 Radiographic evidence of joint damage 31 (14%) 56 (17%) 117 (15%) 0.55 0.28
 ANA positive 96 (43%) 139 (43%) 334 (42%) 0.81 0.96
 History of uveitis 19 (9%) 19 (6%) 80 (10%) 0.86 0.23
 Uveitis complications 0 7 (2%) 22 (3%) <0.01 0.05
 Any conventional DMARD use 201 (91%) 287 (89%) 719 (91%) 0.86 0.53
 Any biologic DMARD use 84 (38%) 174 (54%) 691 (87%) <0.01 <0.01
  1. ANA antinuclear antibody, DMARD disease-modifying antirheumatic drug, IQR interquartile range, RF rheumatoid factor
  2. 1Refers to discontinuation from all DMARDs for at least 30 days for well-controlled JIA
  3. 2P-values calculated by Wilcoxon rank sum testing for continuous variables and chi-square or Fisher's exact test for categorical variables